Wilson Sonsini Goodrich & Rosati advised SR One, Norwest Venture Partners, and Delos Capital on the transaction. Zenas BioPharma, a clinical-stage global biopharmaceutical company, announced an...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction. Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, announced the close of a $103 million Series A...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented ImmunityBio in the transaction. ImmunityBio, Inc., a clinical-stage immunotherapy company announced an up to $320 million royalty financing and equity...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Versant Ventures and New Enterprise Associates on the deal. Nexo Therapeutics (Nexo) announced it has emerged from stealth with $60 million...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Pacific Biosciences of California on the offering, and Davis Polk advised the representatives of the several underwriters involved. Pacific Biosciences of California Inc. announced...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised lead investor Enavate Sciences and new investor Longitude Capital in the financing. Global pharmaceutical company Zenas BioPharma announced a $118...
You must be a Standard 1 Year member to access this content.
